HYBRID EVENT: You can participate in person at Barcelona, Spain or Virtually from your home or work.

Haitang Xie

 

Haitang Xie

Yijishan Hospital of Wannan Medical College, China

Abstract Title:

Biography:

Xie Haitang, Ph.D, Level-2 Professor, Master's Supervisor, Director of Center for Drug Clinical Evaluation of the First Affiliated Hospital of Wannan Medical College. Executive Editor-in-Chief of “Chinese Journal of Clinical Pharmacology and Therapeutics”, Outstanding Editor-in-Chief in East China. Vice Chairman and Standing Committee Member of the 11th Quantitative Pharmacology Professional Committee of the Chinese Pharmacological Society, National Outstanding Scientific and Technological Worker, the first batch of external experts of Center for Drug Evaluation of the National Medical Products Administration,.Hosted several international academic conferences on “Quantitative Pharmacology and New Drug Evaluation” and national continuing education projects, and has been invited for many domestic and international academic reports.

Research Interest:

Background?The Recombinant Omicron BA.4/5-Delta COVID-19 Vaccine (ZF2202-A) is primarily designed for the Delta and Omicron BA.4/5 variants. Our objective was to assess the safety and immunogenicity of ZF2202-A in Chinese adults.

Methods: A total of 450 participants aged ≥18 years, who had completed primary or booster vaccination with a COVID-19 vaccine more than 6 months prior, were enrolled in this randomized, double-blind, active-controlled trial. Participants in the study and control groups were administered one dose of ZF2202-A and ZF2001, respectively. Immunogenicity subgroups were established in each group.

Results: At 14 days after vaccination, the seroconversion rates of Omicron BA.4/5, BF.7, and XBB.1 in the ZF2022-A group were 67.7%, 58.6%, and 62.6%, with geometric mean titers (GMTs) of neutralizing antibodies at 350.2, 491.8, and 49.5, respectively. The main ARs were vaccination site pain, pruritus, fatigue, and asthenia in both the ZF2022-A group and ZF2001 group.

Conclusions: The novel bivalent vaccine ZF2202-A demonstrated satisfactory immunogenicity and safety against Omicron variants as booster dose in adults with prior vaccination of COVID-19 vaccines.